Product logins

Find logins to all Clarivate products below.


Cystic Fibrosis – Epidemiology – Epidemiology Dashboard

Clarivate Epidemiology’s coverage of cystic fibrosis comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of cystic fibrosis for each country, as well as annualized case counts projected to the national population.

Clarivate Epidemiology’s cystic fibrosis will answer the following questions:

  • Of all people with cystic fibrosis, how many in each country across the major mature pharmaceutical markets have been formally diagnosed?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of cystic fibrosis over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology provides at least ten years of forecast data for the following subpopulations:

  • Total prevalent cases by diagnosis status.
  • Diagnosed prevalent cases by mutation status.
  • Birth incident cases

Note: Coverage may vary by country.

Related Market Assessment Reports

Report
Asthma – Landscape & Forecast – Disease Landscape & Forecast (G7)
The asthma therapy market consists of many well-established drugs, including inhaled agents (e.g., GlaxoSmithKline’s Advair / Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim’s Spiriva…
Report
Chronic Obstructive Pulmonary Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Obstructive Pulmonary Disease (US)
Long-acting beta2 agonist (LABA) / long-acting muscarinic antagonist (LAMA) / inhaled corticosteroid (ICS) fixed-dose combinations (FDCs)—i.e., Trelegy and Breztri—have been gaining traction in…
Report
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of CIDP comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy,…
Report
Inflammatory Myositis – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of inflammatory myositis (IM) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…
Report
Chronic Obstructive Pulmonary Disease – Landscape & Forecast – Disease Landscape & Forecast (G7)
The chronic obstructive pulmonary disease (COPD) market continues to gradually shift away from LABA/ICS FDCs toward LABA/LAMA FDCs and LABA/LAMA/ICS FDCs, but current and emerging generics are…